|20.81|| +0.28 / +1.36%|
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. It operates through the following segments U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Branded Pharmaceuticals offers products that focus on the treatment and management of conditions in urology, urologic oncology, endocrinology, and orthopedics. The U.S. Generic pharmaceuticals segment consist of a differentiated product portfolio including high-barrier-to-entry products, first-to-file or first-to-market opportunities that are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. The Devices segment offers medical devices that deliver innovative medical technology solutions to physicians treating female incontinence and pelvic floor repair. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded on October 31, 2013 and is headquartered Dublin, Ireland.
|Paul V. Campanelli||President, Chief Executive Officer & Director|
|Robert J. Cobuzzi||SVP-Operations, Research & Development Strategy|
|Suketu P. Upadhyay||Chief Financial Officer & Executive Vice President|
|Susan T. Hall||Chief Scientific Officer & Executive VP|
|Craig Paterson||Chief Medical Officer|